Response Status for Different Morphologies by Treatment Regimen
| Response . | Treatment Regimen . | |||||
|---|---|---|---|---|---|---|
| Regimen A (VBMCP) . | Regimen B (VBMCP + HiCy) . | Regimen C (VBMCP + rIFNα2) . | ||||
| Non-PB N (%) . | PB N (%) . | Non-PB N (%) . | PB N (%) . | Non-PB N (%) . | PB N (%) . | |
| Objective | 105 (66.5) | 8 (47.1) | 71 (69.6) | 5 (62.5) | 105 (71.9) | 8 (72.7) |
| No change | 28 (17.7) | 3 (17.6) | 21 (20.6) | 0 (0.0) | 28 (19.2) | 1 (9.1) |
| Progression* | 25 (15.8) | 6 (35.3)3-152 | 10 (9.8) | 3 (37.5) | 13 (8.9) | 2 (18.2) |
| Total3-151 | 158 (100) | 17 | 102 (100) | 8 | 146 (100) | 11 (100) |
| Response . | Treatment Regimen . | |||||
|---|---|---|---|---|---|---|
| Regimen A (VBMCP) . | Regimen B (VBMCP + HiCy) . | Regimen C (VBMCP + rIFNα2) . | ||||
| Non-PB N (%) . | PB N (%) . | Non-PB N (%) . | PB N (%) . | Non-PB N (%) . | PB N (%) . | |
| Objective | 105 (66.5) | 8 (47.1) | 71 (69.6) | 5 (62.5) | 105 (71.9) | 8 (72.7) |
| No change | 28 (17.7) | 3 (17.6) | 21 (20.6) | 0 (0.0) | 28 (19.2) | 1 (9.1) |
| Progression* | 25 (15.8) | 6 (35.3)3-152 | 10 (9.8) | 3 (37.5) | 13 (8.9) | 2 (18.2) |
| Total3-151 | 158 (100) | 17 | 102 (100) | 8 | 146 (100) | 11 (100) |
*Progression without response.
Eleven patients were unevaluable for response: 3 in treatment A, 4 in treatment B, and 4 in treatment C. All were in the non-PB group except 1 in treatment C in the PB group.
Represent statistically significant response status differences between PB and non-PB (P < .05). Among the PB cases there were no significant differences in response status using the different regimens.